Ratings Namwiwat Medical Corporation

Equities

End-of-day quote Thailand S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
4.78 ^THB	+0.84%		-7.18%	-31.22%

May. 14	Namwiwat Medical Corporation Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	96,250,000 Shares of Namwiwat Medical Corporation Public Company Limited are subject to a Lock-Up Agreement Ending on 30-APR-2024.	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.

	1st Jan change	Capi.	ESG Refinitiv
NAMWIWAT MEDICAL CORPORATION	-31.22%	92.63M	-
ABBOTT LABORATORIES	-5.43%	181B	C+
MEDTRONIC PLC	+4.30%	114B	C
BECTON, DICKINSON AND COMPANY	-3.09%	68.29B	A
DEXCOM, INC.	+5.86%	52.24B	B-
CENCORA, INC.	+8.15%	44.3B	B-
HOYA CORPORATION	+6.64%	42.73B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+25.54%	32.52B	B
TERUMO CORPORATION	+20.10%	26.02B	A-
WEST PHARMACEUTICAL SERVICES, INC.	+1.00%	25.91B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality